Kang Wei

Dr. Kang Wei

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MZMeng Zheng
Meng Zheng
YZYuanli Zhu
Yuanli Zhu
KWKang Wei
Kang Wei
HPHongxu Pu
Hongxu Pu
RPRenpeng Peng
Renpeng Peng
XSXuying Sun
Xuying Sun
Osteoarthritis (OA), the most common chronic inflammatory joint disease, is characterized by progressive cartilage degeneration, subchondral bone sclerosis, synovitis, and osteophyte formation. Metformin, a hypoglycemic agent used in the treatment of type 2 diabetes, has been evidenced to have anti-inflammatory properties to treat OA. It hampers the M1 polarization of synovial sublining macrophages, which promotes synovitis and exacerbates OA, thus lessening cartilage loss. In this study, metformin prevented the pro-inflammatory cytokines secreted by M1 macrophages, suppressed the inflammatory response of chondrocytes cultured with conditional medium (CM) from M1 macrophages, and mitigated the migration of M1 macrophages induced by interleukin-1ß (IL-1ß)-treated chondrocytes in vitro. In the meantime, metformin reduced the invasion of M1 macrophages in synovial regions brought about by the destabilization of medial meniscus (DMM) surgery in mice, and alleviated cartilage degeneration. Mechanistically, metformin regulated PI3K/AKT and downstream pathways in M1 macrophages. Overall, we demonstrated the therapeutic potential of metformin targeting synovial M1 macrophages in OA.

9 June 2025 in Cellular & Molecular Biology Letters
Verified
Journal Article
Open access
PDF file
JSJingyue Su
Jingyue Su
XSXuying Sun
Xuying Sun
XCXin Chen
Xin Chen
KWKang Wei
Kang Wei
DLDanni Luo
Danni Luo
Zhenhan DengZhenhan Deng
Zhenhan Deng
Osteoarthritis (OA) is a chronic joint disease characterized by cartilage degeneration with unclear pathogenic mechanism. This study aims to discuss the regulatory role of cancerous inhibitor of protein phosphatase 2A (CIP2A) in OA pathogenesis and to elucidate the molecular mechanisms. Mouse chondrocytes were induced by interleukin-1β (IL-1β) to mimic OA inflammation, and extracellular matrix (ECM) homeostasis and inflammatory factors were evaluated at mRNA and protein levels. A mouse model of OA was induced by destabilization of medial meniscus (DMM) surgery. Histopathological staining was used to assess the cartilage destruction of human and mouse. Osteophyte formation was observed using micro-computed tomography (CT). Downstream of CIP2A was screened by RNA sequencing and coimmunoprecipitation coupled with mass spectrometry in mouse chondrocytes. CIP2A was downregulated in cartilage of patients with OA and DMM mouse models, as well as in IL-1β-induced mouse chondrocytes. However, CIP2A overexpression promoted ECM degradation and inflammatory processes and exacerbated cartilage destruction and osteophyte formation. By contrast, knockdown or pharmacological inhibition of CIP2A alleviated cartilage degeneration to a certain extent, with no improvement in osteophytes formation caused by OA. Mechanistically, CIP2A interacted with its downstream cell migration-inducing protein (CEMIP) and activated the nuclear factor kappa B (NF-κB) signaling pathway, resulting in the imbalance of cartilage anabolic and catabolic factors and the activation of inflammation in the development of OA. In addition, CIP2A was ubiquitinated in mouse chondrocytes, causing it to be degraded, which could be a negative feedback of CIP2A expression in OA. CIP2A targets CEMIP to activate NF-κB signaling pathway, which in turn aggravates cartilage destruction and inflammation and ultimately accelerates OA development. Our results suggest the potential role of the CIP2A/CEMIP axis as a therapeutic target for OA.

22 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
YZYi Zou
Yi Zou
JHJinxi Hu
Jinxi Hu
TMTian Ma
Tian Ma
JLJiawei Liu
Jiawei Liu
CYChengla Yi
Chengla Yi
KWKang Wei
Kang Wei
Osteoarthritis (OA) is a degenerative joint disease. CASA1, encoded by CSN1S1, was identified to trigger the secretion of pro-inflammatory cytokines. However, its specific pathogenic role and the underlying molecular mechanisms in OA progression remain elusive. We analyzed the expression of CASA1 in human OA infrapatellar fat pad and synovium using single-cell RNA sequencing, and immunohistochemistry. The functional effects of CASA1 were evaluated in primary chondrocytes and in mouse models. Pain sensitivity and gait alterations were assessed using Von Frey and TreadScan tests. Cartilage degeneration was evaluated by MicroCT, histology, and OARSI scoring. Mechanistic explorations were conducted via RNA-seq, western blotting, transmission electron microscopy (TEM), and untargeted metabolomics. Rescue experiments were performed using Caffeic Acid Phenethyl Ester (CAPE) to validate the pathways involved. CASA1 was significantly overexpressed in OA infrapatellar fat pad and synovium. Functionally, CASA1 suppressed anabolism while promoting catabolism in chondrocytes. In vivo, intra-articular injection of CASA1 induced pain hypersensitivity, gait disorders, osteophyte formation, and severe cartilage erosion, accompanied by elevated inflammatory. Mechanistically, CASA1 activated the NF-κB and MAPK pathways. Furthermore, CASA1 triggered mitochondrial dysfunction via glutathione depletion, as confirmed by TEM and metabolomic profiling. Notably, pharmacological inhibition of NF-κB/MAPK by CAPE effectively reversed CASA1-induced chondrocyte degeneration in vitro and significantly alleviated pain, gait abnormalities, and cartilage damage in vivo. Our findings demonstrated that CASA1 serves as a novel factor driving OA pathogenesis through the activation of NF-κB/MAPK cascades and GSH-depletion-mediated mitochondrial injury. Targeting CASA1 downstream pathways, particularly with CAPE, may represent a promising therapeutic approach for OA treatment.